



BeOne Medicines Austria GmbH

TRANSPARENCY METHODOLOGY NOTES

REPORTING YEAR 2025

TABLE OF CONTENTS

TABLE OF CONTENTS.....	1
1.0 General principles and purpose	2
2.0 Definitions	2
3.0 Date Methodology	5
4.0 Disclosed values	6
5.0 Disclosure of cross border transactions	7
6.0 Consent Management.....	7
7.0 Timing of Disclosure.....	8
8.0 Public disclosure and retention period	8
9.0 GLOSSARY OF TERMS	8



BeOne Medicines Austria GmbH

TRANSPARENCY METHODOLOGY NOTES

REPORTING YEAR 2025

1.0 General principles and purpose

Our Vision is to transform the biotechnology industry, creating impactful medicines that will be affordable and accessible to more cancer patients worldwide.

At BeOne, we uphold the highest standards of transparency. In strict accordance with Applicable Laws, internal codes, and Regulations, we are required to disclose all payments or transfers of value to Healthcare Professionals (HCPs) and/or Healthcare Organizations (HCOs) and Patient Organizations.

To ensure compliance with the applicable local codes, BeOne and the third parties acting on its behalf have established processes and internal procedures to capture every transfer of value made, directly or indirectly, to any individual or organization within the scope of the applicable local pharmaceutical association and its transparency code.

In Austria, BeOne is a member of PHARMIG – Verband der pharmazeutischen Industrie Österreichs (the Association of the Austrian Pharmaceutical Industry) and, as a member, is required to disclose transfers of value to HCPs and HCOs in accordance with Article 9 of the PHARMIG Code of Conduct (PHARMIG-Verhaltenscodex, VHC), which implements the EFPIA HCP/HCO Disclosure Code within the Austrian self-regulatory framework. These methodology notes are prepared in line with the structure for methodological guidance on HCP/HCO disclosure set out in Annex B of the EFPIA Code of Practice and with the transparency requirements of Article 9 of the PHARMIG Code of Conduct.

With effect from 27 May 2025, the company changed its name from “BeiGene Austria GmbH.” to “BeOne Medicines Austria GmbH. The change is part of the global rebranding of **BeiGene, Ltd. to BeOne Medicines**, following the company's redomiciliation to Switzerland. The global name change became effective in **May 2025**, while the Austrian subsidiary officially adopted the new legal name on **1 July 2025**.”. This was a change of name only and not a change of legal entity. Transfers of value disclosed under the BeiGene name in previous reporting years and those disclosed under the BeOne name from this reporting year onwards therefore relate to the same company, so that related disclosures can be tracked across reporting periods.

2.0 DEFINITIONS

Below are some work assumptions and definitions of recipients and expenses that are in scope:

Products in scope: The disclosure covers transfers of value connected with prescription-only medicinal products for human use, whether generic or branded. Transfers of value relating to over-the-counter products, medical devices and other products outside this scope are not included in this disclosure report.

METHODOLOGY NOTE
TRANSPARENCY PROCESS REPORT REQUIREMENTS



BeOne Medicines Austria GmbH

TRANSPARENCY METHODOLOGY NOTES

REPORTING YEAR 2025

2.1. Recipients

Healthcare Organization (HCO):

any legal person/entity that is a healthcare, medical or scientific association or organization (irrespective of the legal or organizational form) such as a hospital, clinic, foundation, university or other teaching institution or learned society; whose business address, place of incorporation or primary place of operation is in Europe or through which one or more HCPs provide services.

Healthcare Professional (HCP):

any natural person that is a member of the medical, dental, pharmacy or nursing professions, or any other person who, in the course of his or her professional activities, may prescribe, purchase, supply, recommend or administer a Medicinal Product, and whose primary practice, principal professional address or place of incorporation is in Europe, specifically in Germany.

Patient Organization (PATORG)

“Not-for-profit organizations (including the organizations to which they are affiliated) based or active in Germany, which consist primarily of patients or their carers and which represent or support the needs of patients or their carers. This definition also includes persons who represent and/or formulate the collective concerns and interests of a patient organization in relation to a specific topic or a specific pathology.”

Third party and PCO (Partners in Congress Organization)

Third parties are entities or individuals that represent our company in the marketplace or that interact with other third parties on behalf of our company or in relation to our company's products. Among others, these third parties can be distributors, travel agents, consultants and contract research organizations.

Retired and deceased recipients: Transfers of value to retired HCPs are disclosed where the recipient still met the definition of an HCP at the time the transfer of value was made. Where BeOne becomes aware that a recipient is deceased, the related transfers of value are reported in the aggregate section of the disclosure report rather than on a named individual basis, in line with PHARMIG guidance.

2.2. Expense type

Donations and Grants to HCOs

This category covers support provided only to healthcare organizations, institutions or associations.

Events include all scientific professional meetings, congresses, conferences, symposia and other similar events.

METHODOLOGY NOTE
TRANSPARENCY PROCESS REPORT REQUIREMENTS



BeOne Medicines Austria GmbH

TRANSPARENCY METHODOLOGY NOTES

REPORTING YEAR 2025

Sponsorships

This category provides financial support to HCOs/third party appointed by an HCO to manage an Event (for example, PCO).

This category could also contain payments related to a Congress or Symposia paid to an HCO on behalf of an entity disclosed on an individual basis (in the name of the HCO).

Examples:

- Rental of booth space at an event
- Advertisement space
- Satellite symposia at a Congress
- Sponsoring of speakers/faculty

Registrations fees

This category always related to an HCP attending a Congress or Symposia.

Travel & Accommodation expenses

This category related to attending a Congress or Symposia.

Example:

- Fees for airfare, train, boat or ferry (incl. booking fees)
- Car rental, car services, taxi transfers
- Parking fees
- Gas/Petrol costs
- Road tolls or fees
- Hotel Lodging

Fee for service

TOVs resulting from or related to contracts between BeOne and institutions, organisations, associations or HCPs under which such institutions, organisation, association or HCPs provide any type of services to BeOne, or any other type of funding not covered in the previous categories.

TOVs related to R&D related activities but when they do not follow within the definition of R&D TOVs (transfer of values) as defined by EFPIA are disclosed under this category.

Examples include:

- Speaker fees
- Speaker training

Research & Development:

This category related to R&D TOVs to HCPs/HCOs associated with:

- Non-clinical (Good Laboratory Practice (GLP))

METHODOLOGY NOTE
TRANSPARENCY PROCESS REPORT REQUIREMENTS



BeOne Medicines Austria GmbH

TRANSPARENCY METHODOLOGY NOTES

REPORTING YEAR 2025

- Clinical trials in Phase I to Phase IV (Interventional and Non-Interventional Prospective)
- Investigator initiated and sponsored Studies
- Collaborative initiated Research studies

Transfers of value out of scope (excluded)

Certain transfers of value fall outside the scope of this disclosure and are not reported, including: transfers that form part of the ordinary course of the purchase and sale of medicinal products (such as trade discounts and rebates); the provision of medical samples; informational or educational materials and items of medical utility within the applicable thresholds; and meals and beverages within the limits permitted by the Pharmig code. Transfers of value to recipients located outside Germany are not reported here but are disclosed in the relevant country.

3.0 DATE METHODOLOGY

BeOne followed the date methodology when determining which TOVs are in scope for current reporting cycle:

Event date:

Related to the date that the expense occurred under the following categories:

- Contribution to cost of events: Registration fee
- Contribution to cost of events: Travel & Accommodation

Where BeOne sponsors an HCP's participation in a specific event and later reimburses the associated costs against an invoice, the date on which that invoice is paid is used as both the event start date and the event end date, as no separate event date is captured in these cases.

Payment date:

Related to the date that the payment was provided to the covered recipient under following categories:

- Fee for services and consultancy: fees
- Sponsorships
- Grant & Donation
- Research & Development

Multi-year agreements: Where a contract or transfer of value spans more than one reporting year, the value is allocated to the reporting year in which each underlying activity takes place or each payment is made, applying the event-date and payment-date rules set out above. A single multi-year agreement may therefore give rise to disclosures across several reporting years.



BeOne Medicines Austria GmbH

TRANSPARENCY METHODOLOGY NOTES

REPORTING YEAR 2025

4.0 DISCLOSED VALUES

4.1. Tax and VAT

In general, BeOne excludes Tax and VAT for Monetary payments/transfers of value (TOVs), inclusive from all R & D TOVs (Transfer of value). Because some amounts are obtained from external data providers, it is possible that a limited number of transactions still include VAT. VAT is excluded for all R&D TOVs (transfers of value).

4.2. Disclosure currency

All payments and transfers of value are disclosed in the local currency, which for Germany is the Euro (EUR). If a payment is made in another currency, it is converted into EUR using the daily exchange rate applicable on the date on which the transfer of value occurred.

4.3. Cancellation of events or when an HCP does not participate.

Where a flight or accommodation is booked but the event is subsequently cancelled, or the HCP does not attend, no transfer of value is attributed to that HCP or HCO.

4.4. Transfer of Values (TOVs)

Direct and indirect transfers of value, whether in cash (Monetary), In Kind or otherwise, made, whether for promotional purposes or otherwise, in connection with the development and sale of generic or branded prescription-only Medicinal Products exclusively for human use.

- **Direct transfers of value** - are those made directly by BeOne to, and for the benefit of an HCP/HCO/Third Party Intermediary (where identity of HCP/HCO cannot be identified) Recipient.
- **Indirect transfers of value** - are those made through an intermediary (Third Party/PCO) on behalf of BeOne for the benefit of an HCP/HCO Recipient, where the identity of BeOne is known to or can be identified by the Recipient and where BeOne can identify the HCP/HCO that benefits from the TOV. (For example, single-blinded or double-blinded market research are excluded).

Examples:

- In Kind –Lodging, Transportation, Registration Fees
- Monetary – Grant, Sponsorship, Donation, Research and Fee for Service payments



BeOne Medicines Austria GmbH

TRANSPARENCY METHODOLOGY NOTES

REPORTING YEAR 2025

4.5. Individual and aggregate disclosure

To the extent permitted, transfers of value are disclosed on an individual, named basis where the recipient has consented to individual disclosure. Where individual disclosure is not possible – for example, where consent has not been given or has been withdrawn, or where disclosure on a named basis is not permitted for legal reasons – the relevant transfers of value are reported in aggregate. In line with the Pharmig Transparency Code and the EFPIA Code, all Research & Development transfers of value are disclosed on an aggregate basis.

4.6. Self-incorporated HCPs

Where an HCP provides services through his or her own company or other legal entity (a self-incorporated HCP), the related transfer of value is disclosed either under the individual HCP or under that entity as an HCO, depending on the circumstances of the engagement and the information available to BeOne.

4.7. Valuation of non-monetary (in-kind) transfers of value

Non-monetary (in-kind) transfers of value, such as travel, accommodation and registration provided directly to a recipient, are disclosed at the actual cost incurred by BeOne or, where the actual cost is not available, at fair market value.

5.0 DISCLOSURE OF CROSS BORDER TRANSACTIONS

BeOne will disclose based on the principal practice address of the recipient, regardless of where payment is made. BeOne relies on IQVIA Data Base as a recognized industry leader in data management to determine the principal practice address of the Healthcare Professional (HCP) and Healthcare Organisation (HCO) to be consistent across the EFPIA countries. This may not match the address collected on the contract, our finance payment system, or other supporting documentation.

6.0 CONSENT MANAGEMENT

BeOne collects consent for individual disclosure digitally using a OneTrust link. The link is sent together with the contract to the HCP (and to HCOs where applicable, based on local requirements) with whom BeOne is engaged or has an interaction; the contract partner submits the consent link and receives a confirmation of his or her decision.

Data protection legal basis: Individual disclosures of personal data relating to HCPs (and HCOs where applicable) are made on the basis of the recipient's prior consent, in accordance with the EU General Data Protection Regulation (GDPR). Where consent is not given, the relevant transfers of value are disclosed in aggregate. BeOne has appropriate arrangements in place to disclose this information lawfully, and recipients are informed of the disclosure process at the time of contracting.

METHODOLOGY NOTE
TRANSPARENCY PROCESS REPORT REQUIREMENTS



BeOne Medicines Austria GmbH

TRANSPARENCY METHODOLOGY NOTES

REPORTING YEAR 2025

To avoid the “cherry picking” of transactions for individual disclosure:

- If different consent is given for the engagements by an HCP, BeOne will disclose TOVs based on the latest decision of the HCP.

In case HCP/HCO revoking of individual consent:

If an HCP or HCO revokes consent before the data is published, BeOne will update the data and include the TOVs in the aggregate section of the applicable Disclosure report.

- If an HCP or HCO revokes consent after publication of the data, BeOne will update the information retrospectively or prospectively based on local requirements at the first reasonable time.

7.0 TIMING OF DISCLOSURE

BeOne will publish the data for the prior period on or before June 30, following the local association's instructions.

8.0 PUBLIC DISCLOSURE AND RETENTION PERIOD

Disclosure platform: The disclosure report is published on a publicly accessible in our website BeOne in accordance with the Pharmig Transparency Code.

Disclosure language: In accordance with the Pharmig Transparency Code, the disclosure report and these methodology notes are made available in German and English.

Per the PHARMIG's guidance, BeOne will ensure that the Disclosed reports remain in the public domain for three years.

The documentation related to the reported activities will remain in our archives, documented, and retained for five years.

Data quality checks: Before publication, BeOne carries out internal quality checks on the data to be disclosed. These checks include the validation and reconciliation of recipient information, transfer-of-value categories and amounts against the underlying source systems, in order to confirm that the disclosure is accurate and complete.

9.0 GLOSSARY OF TERMS

METHODOLOGY NOTE
TRANSPARENCY PROCESS REPORT REQUIREMENTS



BeOne Medicines Austria GmbH

TRANSPARENCY METHODOLOGY NOTES

REPORTING YEAR 2025

TERM	DEFINITION
HCP	Healthcare professional
HCO	Healthcare Organization
PHARMIG	Verband der pharmazeutischen Industrie Österreichs
TOV	Transfer of Value
R & D	Research & Development
PCO	Partners in Congress organization
EFPIA	European Federation of Pharmaceutical Industries and Associations
PATORG	Patient Organization
IQVIA	External data provider whose database is used to determine the principal practice address of HCPs and HCOs
GDPR	General Data Protection Regulation (Regulation (EU) 2016/679)
GLP	Good Laboratory Practice

----- End of document -----

METHODOLOGY NOTE
TRANSPARENCY PROCESS REPORT REQUIREMENTS